Cargando…

Antioxidant Therapy in Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis (NASH) affects up to 3% of the North American population. It occurs as a manifestation of the insulin-resistant state and oxidative stress is thought to be a key component of its pathophysiology. Exercise and diet, which are the mainstay of therapy, are difficult to achi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Busafi, Said A., Bhat, Mamatha, Wong, Philip, Ghali, Peter, Deschenes, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512254/ https://www.ncbi.nlm.nih.gov/pubmed/23227320 http://dx.doi.org/10.1155/2012/947575

Ejemplares similares

Endoscopic Management of Portal Hypertension
por: Al-Busafi, Said A., et al.
Publicado: (2012)

Chylous Ascites: Evaluation and Management
por: Al-Busafi, Said A., et al.
Publicado: (2014)

Prevention and Management of Chronic Hepatitis B
por: Bhat, Mamatha, et al.
Publicado: (2014)

Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis
por: Sebastiani, Giada, et al.
Publicado: (2015)

Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection
por: Benmassaoud, Amine, et al.
Publicado: (2018)

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
por: Sumida, Yoshio, et al.
Publicado: (2020)

Nonalcoholic Fatty Liver Disease: Noninvasive Methods of Diagnosing Hepatic Steatosis
por: AlShaalan, Rasha, et al.
Publicado: (2015)

Incidence and Predictors of Advanced Liver Fibrosis by a Validated Serum Biomarker in Liver Transplant Recipients
por: Bhat, Mamatha, et al.
Publicado: (2017)

Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology
por: Yoon, In Cheol, et al.
Publicado: (2019)

The metabolic basis of nonalcoholic steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

The Immune Landscape in Nonalcoholic Steatohepatitis
por: Narayanan, Sowmya, et al.
Publicado: (2016)

Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome
por: Shengir, Mohamed, et al.
Publicado: (2020)

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
por: Parthasarathy, Gopanandan, et al.
Publicado: (2020)

Adipokines in Nonalcoholic Steatohepatitis: From Pathogenesis to Implications in Diagnosis and Therapy
por: Tsochatzis, Emmanuel A., et al.
Publicado: (2009)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options
por: Milic, Sandra, et al.
Publicado: (2015)

New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
por: Mendez-Sanchez, Nahum, et al.
Publicado: (2018)

Necroptosis in Nonalcoholic Steatohepatitis
por: Gautheron, Jérémie, et al.
Publicado: (2015)

Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis
por: Tincopa, Monica A.
Publicado: (2020)

Repurposing drugs to target nonalcoholic steatohepatitis
por: Sookoian, Silvia, et al.
Publicado: (2019)

The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Cha, Ji-Young, et al.
Publicado: (2018)

Antioxidant and Hepatoprotective Effects of Silibinin in a Rat Model of Nonalcoholic Steatohepatitis
por: Haddad, Yara, et al.
Publicado: (2011)

Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status
por: Roy, Partho Pratik, et al.
Publicado: (2022)

Non-alcoholic steatohepatitis in liver transplant recipients diagnosed by serum cytokeratin 18 and transient elastography: A prospective study
por: Alhinai, Alshaima, et al.
Publicado: (2021)

Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
por: Noureddin, Mazen, et al.
Publicado: (2019)

Nonalcoholic steatohepatitis: global impact and clinical consequences
por: Kabarra, Khaled, et al.
Publicado: (2021)

Intestinal Dysbiosis, the Tryptophan Pathway and Nonalcoholic Steatohepatitis
por: Chen, Jiezhong, et al.
Publicado: (2022)

MicroRNAs and Nonalcoholic Steatohepatitis: A Review
por: Morishita, Asahiro, et al.
Publicado: (2023)

Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future
por: Gitto, S., et al.
Publicado: (2015)

Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

Betel Chewing and Nonalcoholic Steatohepatitis
por: Bleibel, Wissam, et al.
Publicado: (2018)

Insulinoma in Patient With Nonalcoholic Steatohepatitis
por: Cain, Daniel, et al.
Publicado: (2023)

Challenges and opportunities in nonalcoholic steatohepatitis
por: Wang, Xiaobo
Publicado: (2022)

Intragastric Balloons: An Emerging Therapy for Nonalcoholic Steatohepatitis and Fibrosis?
por: Jirapinyo, Pichamol, et al.
Publicado: (2019)

Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
por: Sayiner, Mehmet, et al.
Publicado: (2018)

Smad3 Phospho-Isoform Signaling in Nonalcoholic Steatohepatitis
por: Yamaguchi, Takashi, et al.
Publicado: (2022)

Mitochondria and the NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis
por: Torres, Sandra, et al.
Publicado: (2022)

Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH)
por: Qi, Xiaoyan, et al.
Publicado: (2022)

Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
por: Shi, Yi-wen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j6ikh7mbl6ojqoi4leb0ktge4g